Related Experiment Video
Updated: Jan 12, 2026
Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging
Published on: December 8, 2023
IgG-detection devices for the Tus-Ter-lock immuno-PCR diagnostic platform
Isabelle Morin1, Samuel P Askin, Patrick M Schaeffer
1Comparative Genomics Centre, School of Pharmacy & Molecular Sciences, James Cook University, Townsville, QLD, Australia.
Insights
A new quantitative Immuno-PCR (qIPCR) platform using Tus-Ter-lock (TT-lock) technology offers enhanced sensitivity for detecting disease biomarkers. This robust method simplifies Immuno-PCR, overcoming previous limitations for broader diagnostic applications.
Area of Science:
- Biotechnology
- Assay Development
- Molecular Diagnostics
Background:
- Immuno-PCR (IPCR) offers superior sensitivity over traditional immunoassays but faces challenges like high background noise and poor reproducibility.
- Developing homogeneous, universal protein-DNA conjugates is crucial for simplifying IPCR and improving its robustness.
Purpose of the Study:
- To further develop the Tus-Ter-lock (TT-lock) Immuno-PCR platform for quasi-universal quantitative detection of antigens and mammalian IgG.
- To enhance the sensitivity and reproducibility of Immuno-PCR assays for early disease detection.
Main Methods:
- Engineered Tus protein fusions with IgG-binding proteins (Protein G, Protein L, LG chimera) to create homogeneous protein-DNA conjugates.
- Utilized the TT-lock interaction for self-assembly of detection devices on a TT-lock-T template.
- Applied direct and indirect TT-lock Immuno-PCR formats for quantitative detection of antibodies and antigens.
Main Results:
- Direct TT-lock qIPCR detected goat anti-GFP IgG at 0.3 pM and human IgG in serum with high sensitivity.
- Indirect TT-lock qIPCR systems detected 1 pM GFP and 10 pM measles nucleoprotein.
- Demonstrated superior sensitivity of TT-lock Immuno-PCR compared to Protein G-Peroxidase ELISA.
Conclusions:
- The developed TT-lock Immuno-PCR platform provides a robust and highly sensitive method for quantitative detection of various disease biomarkers.
- This technology simplifies Immuno-PCR, addressing key limitations and paving the way for improved early disease diagnostics.
Abstract:
The number of new Immuno-PCR technologies and applications is steadily growing as a result of a general need for more sensitive immunoassays for early detection of diseases. Although Immuno-PCR has been demonstrated to be superior to its immunoassay counterpart, it is still regarded as a challenging technology due to various problems arising from its increased detection power, such as high background noise as well as substantial batch-to-batch reproducibility issues. Current efforts have intensified to produce homogeneous universal protein-DNA conjugates to simplify this technology and render it more robust. We have recently developed a new quantitative Immuno-PCR (qIPCR) technology using the Tus-Ter-lock (TT-lock) interaction to produce homogeneous protein-DNA conjugates that can detect very small numbers of disease-related antibodies. We now report the further development of the TT-lock Immuno-PCR platform for the quasi universal quantitative detection of antigens and mammalian IgG. For this, Tus was fused to various IgG-binding proteins--i.e. protein G, protein L and their LG chimera--and self-assembled to the TT-lock-T template. These detection devices were then evaluated and applied in various direct and indirect Immuno-PCR formats. The direct TT-lock qIPCR could detect goat anti-GFP IgG at concentrations as low as 0.3 pM and total human IgG in serum samples with great sensitivity. Further indirect TT-lock qIPCR systems were developed that could detect 1 pM of GFP and 10 pM of measles nucleoprotein. In all cases, the superiority of the TT-lock Immuno-PCR was demonstrated in terms of sensitivity over an analogous Protein G-Peroxidase ELISA.
